Watch out for BioNTech! Bayer, Formycon, and Vidac Pharma shares are on the rise!

Vidac Pharma: Starting signal for a price rally?

Vidac Pharma shares are currently listed on the regional stock exchanges in Hamburg, Stuttgart, and Berlin. The stock tripled in value last fall after strong research results. Since then, a healthy consolidation has set in. As the news flow surrounding the development of novel cancer therapies remains positive, now is the time for a new price rally. Analysts believe that Vidac shares could multiply in value, and a new price momentum signal has also emerged: listing on a major German stock exchange.

The Company has not yet announced which exchange this will be, but it can only be the Frankfurt Stock Exchange. The process of applying for regulatory approval from the German Federal Financial Supervisory Authority (BaFin) is underway. The move is intended to usher in the next phase of the Company's development and expand its access to international capital markets.

Vidac Pharma has also strengthened its team. Dr. Eyal Breitbart, Ph.D., has been appointed Chief Technology Officer (CTO). He has decades of leadership experience spanning the entire drug development lifecycle and was previously responsible for the Nasdaq-listed company VBL Therapeutics, among other notable roles.

Both measures are part of Vidac Pharma's broader strategy to scale up its development pipeline. The science behind it is particularly compelling: by reversing the Warburg effect, the goal is to restore normal cell metabolism in cancer cells, thereby triggering the death of tumor cells. Analysts at Sphene Capital consider this approach highly promising. The results achieved so far by Almavid and the active ingredient VDA-1102 have been convincing. The analysts have set a price target of EUR 4.30. Vidac shares are currently trading at around EUR 0.50 and therefore offer significant upside potential if clinical progress continues as expected.

Bayer: Will the share price break through the EUR 30 mark?

Bayer shares have performed strongly in recent months, rising by around 50% since April. The share is currently trading just below the EUR 30 mark. Investors have largely ignored the court cases in the US in recent months, instead focusing on the surprisingly positive news flow from the pharmaceutical pipeline.

Last Friday, however, the Leverkusen-based company reported a setback. The possible approval of the menopause drug Elinzanetant in the US will be delayed, as the US Food and Drug Administration (FDA) has extended the review period by up to 90 days. Bayer emphasized that there are no known concerns about the general approvability of the drug for the treatment of hot flashes. In parallel, the DAX-listed company is working to obtain approval for Elinzanetant in the EU and other markets. There were no negative effects on the share price yesterday, and it remained unchanged from Friday.

Formycon: 50% in a few months

Formycon shares have also conjured up a 50% performance since April. The biosimilar specialist recently reported operational progress in the Dahlia pharmacokinetic study of its Keytruda biosimilar, FYB206. According to the report, patient recruitment has been successfully completed. The study is investigating the pharmacokinetics, safety, and tolerability of FYB206 in comparison to Keytruda.

Keytruda is used to treat various types of cancer, including melanoma, lung cancer, head and neck tumors, bladder and kidney cancer, and certain forms of stomach and uterine cancer. It is one of the world's best-selling drugs, generating approximately USD 29.5 billion in revenue for Merck & Co. in 2024. Due to its wide range of applications, revenues are expected to continue to rise in the coming years. Formycon aims to grab a slice of this billion-dollar pie in the future. Following FDA approval, an optimized development program without a Phase III study is planned. This will save time and money.

RBC considers FYB206 to be a very promising biosimilar candidate. Analysts recommend the stock at EUR 51.

Vidac Pharma shares are at an attractive entry point. The stock has not reacted to the positive news flow of recent months. The upcoming listing on a major German stock exchange could serve as a starting signal for a new rally. In any case, the downside risk appears to be limited. Bayer and Formycon have shown that a 50% gain is possible in just a few months. For both, the short-term upward trend remains intact, but a breather is likely.